الفهرس | Only 14 pages are availabe for public view |
Abstract Hyperphosphatemia has been reported to induce extraskeletal calcification of soft tissue particularly in the heart as well as bone disease; a link has been reported between gastric hyperacidity and hyperphosphatemia in patients with renal dieses undergoing hemodialysi. Objective: The purpose of this study was to compare the effect of Famotidine versus Omeprazole on the efficacy of calcium carbonate as phosphate binder in haemodialysis patients. Methods: from February 2014 to June 2014 total number of 64 patients of both sexes were recruited from Department of Renal Dialysis, Tanta University Hospital, Egypt. Patients were categorized into 3 groups. group I (control group) consisted of 20 Patients (10) females and (10) males took calcium carbonate (CaCO3) (2.5 – 4 g/day) only, group II consisted of 21 Patients (13) females and (8) males took the same dose of CaCO3 with famotidine 10 mg/day and group III consisted of 23 Patients (8) females and (15) male took the same dose CaCO3 with omeprazole 20 mg/day. 5 ml blood was collected from antecubital vein by 5 ml syringe at the start of the study and monthly for four monthes during hemodialysis sessions for the assessment of serum calcium, phosphorus, alkaline phosphates and parathyroid hormone levels. Results: All data are expressed as the mean ±SD. group II showed significant increase (p< 0.05) in serum phosphorus at 3rd month with significant decreased (p< 0.05) in serum calcium comparing with pretreatment value was detected, howeever no significant change in parathyroid hormone (PTH) level. Abstract II group III showed no significant change in serum calcium, phosphorus and PTH levels comparing with pretreatment values. Both groups (II and III) showed significant decrease in alkaline phosphatase (ALP) level (p< 0.05). Conclusion: Co-administration of famotidine with calcium carbonate aggravates hyperphosphatemia and this may increase the incidence of complications. The efficacy of calcium carbonate as a phosphate binder was not affected by co-administration of omeprazole. |